Erythropoietin Decreases Renal Fibrosis in Mice with Ureteral Obstruction
- 1 May 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 18 (5) , 1497-1507
- https://doi.org/10.1681/asn.2005080866
Abstract
The inhibitory effects of recombinant human erythropoietin (rhEPO) were examined against (1) the progression of renal fibrosis in mice with complete unilateral ureteral obstruction and (2) the TGF-β1–induced epithelial-to-mesenchymal transition (EMT) in MDCK cells. Unilateral ureteral obstruction was induced in BALB/c mice and rhEPO (100 or 1000 U/kg, intraperitoneally, every other day) or vehicle was administered from day 3 to day 14. Immunoblotting and immunohistochemistry revealed increased expressions of TGF-β1, α-smooth muscle actin (α-SMA), and fibronectin and decreased expression of E-cadherin in the obstructed kidneys. In contrast, rhEPO treatment significantly attenuated the upregulation of TGF-β1 and α-SMA and the downregulation of E-cadherin. MDCK cells were treated with TGF-β1 (5 ng/ml) for 48 h to induce EMT, and the cells were then co-treated with TGF-β1 and rhEPO for another 48 h. Increased expressions of α-SMA and vimentin and decreased expressions of zona occludens–1 and E-cadherin were observed after TGF-β1 treatment, and these changes were markedly attenuated by rhEPO co-treatment. TGF-β1 increased phosphorylated Smad-2 expression in MDCK cells, which was decreased by rhEPO co-treatment. In conclusion, rhEPO treatment inhibits the progression of renal fibrosis in obstructed kidney and attenuates the TGF-β1–induced EMT. It is suggested that the renoprotective effects of rhEPO could be mediated, at least partly, by inhibition of TGF-β1–induced EMT.Keywords
This publication has 34 references indexed in Scilit:
- Involvement of Renal Progenitor Tubular Cells in Epithelial-to-Mesenchymal Transition in Fibrotic Rat KidneysJournal of the American Society of Nephrology, 2005
- Renoprotective effect of erythropoietin (EPO): Possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidneyKidney International, 2005
- Angiotensin II AT1receptor blockade decreases vasopressin-induced water reabsorption and AQP2 levels in NaCl-restricted ratsAmerican Journal of Physiology-Renal Physiology, 2005
- Attenuation of Interstitial Inflammation and Fibrosis by Recombinant Human Erythropoietin in Chronic Cyclosporine NephropathyAmerican Journal of Nephrology, 2005
- Erythropoietin Protects the Kidney against the Injury and Dysfunction Caused by Ischemia-ReperfusionJournal of the American Society of Nephrology, 2004
- Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trialKidney International, 2004
- EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidneyKidney International, 2004
- Erythropoietin protects against ischaemic acute renal injuryNephrology Dialysis Transplantation, 2004
- Smad7 Inhibits Fibrotic Effect of TGF-β on Renal Tubular Epithelial Cells by Blocking Smad2 ActivationJournal of the American Society of Nephrology, 2002
- Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic PatientsNephron, 1997